Acrivon Therapeutics (ACRV)

• Market cap: $52.7M
• 1 day: 4.37%
• 5 days: -5.11%
• 1 month: -44.52%
• 3 months: -16.5%
• 6 months: 29.46%
• Year to date: -32.11%
• 1 year: -74.35%
• 5 years: -89.96%
• 10 years: -89.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Employees: 78